Ligand to Acquire Pharmacopeia for Stock and Contingent Value Rights
Ligand Pharmaceuticals and the SALK Institute Enter Settlement Agreement and Mutual Release of All Claims
Ligand to Hold Second Quarter Results Conference Call on July 31
Ligand Partner GlaxoSmithKline Receives FDA Extended Priority Review for PROMACTA(R) NDA
Ligand to Present at the Needham & Company Biotechnology and Medical Technology Conference on June 11
Ligand Pharmaceuticals Announces First Quarter Results
Ligand Initiates Phase II Trial with LGD-4665 in Idiopathic Thrombocytopenic Purpura
Ligand to Hold First Quarter Results Conference Call on May 1
Ligand Partner GlaxoSmithKline Receives FDA Acceptance and Granted Priority Review for PROMACTA(R) NDA
Ligand Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
Ligand to Hold Fourth Quarter Results Conference Call on February 20
Ligand to Present at BIO CEO and Investor Conference on February 12
Ligand Partner Pfizer Submits NDA for Fablyn(R)
Ligand Pharmaceuticals Awarded U.S. Patent for LGD-4665
